Evidence map›Paper›PMID 40519627›Full record

ArticleNIHR open research2025

Effectiveness of mucoactives (carbocisteine and hypertonic saline) in addition to usual airway clearance management with usual airway clearance management alone in acute respiratory failure (MARCH): study protocol for a multi-centre 2x2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost-effectiveness trial with internal pilot.

Bronwen Connolly, Naomi Dickson, Ashley Agus, Bronagh Blackwood, Mark Borthwick, Judy Bradley, Christina Campbell, Marc Chikhani, Mike Clarke, Paul Dark and 13 more

Abstract read
In one paragraph

Article in NIHR open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Bronwen ConnollyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0000-0002-5676-5497
Naomi DicksonNorthern Ireland Clinical Trials Unit, Belfast, Northern Ireland, UK.
Ashley AgusNorthern Ireland Clinical Trials Unit, Belfast, Northern Ireland, UK.
Bronagh BlackwoodWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0000-0002-4583-5381
Mark BorthwickOxford University Hospitals NHS Foundation Trust, Oxford, England, UK.ORCID https://orcid.org/0000-0002-3249-1508
Judy BradleyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
Christina CampbellNorthern Ireland Clinical Trials Unit, Belfast, Northern Ireland, UK.
Marc ChikhaniUniversity of Nottingham, Nottingham, England, UK.
Mike ClarkeNorthern Ireland Clinical Trials Unit, Belfast, Northern Ireland, UK.
Paul DarkDivision of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, England, UK.
Ranjit LallUniversity of Warwick Warwick Clinical Trials Unit, Coventry, England, UK.
Cliona McDowellNorthern Ireland Clinical Trials Unit, Belfast, Northern Ireland, UK.
Margaret McFarlandPharmacy Department, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Michael McKelveyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
Cecilia O'KaneWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
Brenda O'NeillInstitute of Nursing and Health Research, Ulster University, Coleraine, Northern Ireland, UK.ORCID https://orcid.org/0000-0002-6471-1413
Gavin PerkinsWarwick Clinical Trials Unit, University of Warwick, Coventry, England, UK.
Murali ShyamsundarRegional Intensive Care Unit, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
Gordon SturmeyIndependent Patient Partner, England, UK.
Clifford C TaggartWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
John WarburtonUniversity Hospitals Bristol NHS Foundation Trust, Bristol, England, UK.
Barry WilliamsIndependent Patient Partner, England, UK.
Daniel F McAuleyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Usual airway clearance management in critically ill patients with acute respiratory failure includes suctioning, humidification, use of isotonic saline, and respiratory physiotherapy techniques. Escalation to use of mucoactives occurs when secretions are difficult to clear. Use of mucoactives in clinical practice for this patient population is extensive, yet empirical and variable. Carbocisteine and hypertonic saline are the most used agents, but evidence for their effectiveness is absent or minimal. The lack of existing large-scale randomised trials comparing mucoactives to usual airway clearance management alone in critically ill patients with acute respiratory failure highlights the urgency and necessity of this study. Aim: To determine whether the use of mucoactives in critically ill patients with acute respiratory failure improves clinical outcomes and is cost effective, compared to usual airway clearance management alone. Methods: A UK multi-centre, 2x2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost effectiveness trial with internal pilot. The target sample is 1956 critically ill adults. Participants will be equally allocated across four trial arms. All participants will receive usual airway clearance management. In three intervention groups, participants will receive either carbocisteine, hypertonic saline, or a combination of carbocisteine and hypertonic saline. In the fourth comparator group, participants will receive usual airway clearance management alone. The primary outcome is the duration of mechanical ventilation with secondary clinical, safety, and health resource utilisation outcomes. The trial will be reported in accordance with CONSORT guidelines. Ethical approval was granted by Leeds East (Yorkshire & The Humber) Research Ethics Committee (reference 21/YH/0234) on 28 Trial registration: Main trial: ISRCTN17683568, https://www.isrctn.com/ISRCTN17683568, 25

Indexed as

Acute respiratory failureairway clearancecarbocisteinecritical illnessfactorialhypertonic salinerandomised controlled trial

Identifiers

PMID40519627
PMCPMC12163365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.